Aller au contenu principal
2026 article

Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024–2025 National Multicenter Cross‐Sectional Study

0Citations signalées, ce qui n’est pas une note de qualité
14Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND: This study aimed to investigate the current knowledge, attitudes, and practices of Chinese physicians regarding the management of Helicobacter pylori infection through a large-scale national survey. MATERIALS AND METHODS: This national, multicenter cross-sectional survey was conducted from October 2024 to May 2025 among physicians from over 2200 medical institutions across 31 provinces using an online questionnaire. The survey comprised four dimensions: basic information, knowledge, attitudes, and practices. Results were compared with the Sixth Chinese National Consensus Report on the Management of H. pylori infection and the Maastricht VI/Florence guidelines. Further, subgroup analyzes were conducted. RESULTS: A total of 6030 valid responses were included. Knowledge: Only 27.5% of participants correctly estimated the H. pylori infection rate as 40%-50%, and 13.5% accurately understood the reinfection rate as 2%. Attitude: Overall, 93.4% of participants reported familiarity with Chinese H. pylori guidelines and consensus statements, and 84.1% supported replacing proton pump inhibitors with potassium-competitive acid blockers. PRACTICE: Gaps were observed in recognizing indications for H. pylori eradication, including unexplained iron deficiency anemia (43.9%), primary immune thrombocytopenia (39.6%), vitamin B12 deficiency (32.3%), and H. pylori infection without countervailing factors (36.8%). The bismuth-based quadruple regimen was the most commonly selected first-line treatment (86.7%); however, 74.5% still selected the amoxicillin + clarithromycin combination, despite the high resistance rate associated with clarithromycin. The dual regimen is gradually gaining acceptance (53.9%). Subgroup analyzes: Greater adherence to guideline recommendations was observed among physicians from higher-level medical institutions, gastroenterologists, those with more years of practice, higher professional titles, and educational levels, as well as those practicing in economically developed regions. CONCLUSION: Chinese physicians generally follow guideline-recommended core practices for the diagnosis and treatment of H. pylori. However, notable gaps persist in understanding reinfection rates, identifying appropriate eradication indications, and selecting optimal treatment regimens. Therefore, strengthened educational interventions are warranted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
Current Status of Diagnosis, Treatment, and Prevention of <i>Helicobacter pylori</i> Infection in China: A 2024–2025 National Multicenter Cross‐Sectional Study
Date Crossref
01/07/2026
Éditeur
Wiley
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Helicobacter pylori-related gastroenterology studiesMicroscopic ColitisCeliac Disease Research and Management

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.